ESR1 and cancer: In ER+ breast cancer, cell-specific ARPs indicated increased myeloid inflammatory activity, less metabolically active endothelium, attenuated cancer cell interferon responses, and CD4+/CD8+ T cell quiescence and metabolic dysfunction with age (Fig. 7b).